Furthermore, Jain and co-workers treated glioblastoma-bearing mice with antibodies targeting Ang-2/VEGF (CrossMab, A2V), and found that A2V attenuated microvascular density and polarized M2-like TAMs toward the anti-tumoral M1-like TAMs, leading to the retardation of tumor progression (152). Here, VEGFA is linked to neoplasm.